Rewrite this medical report in very simple plain language. Use short sentences. No medical jargon. Explain every...

May 23, 2026Navis AI

For informational purposes only

This answer was generated by AI grounded in NCCN guidelines and published medical literature. It is not medical advice. Always consult your oncologist or care team before making treatment decisions.

Question asked:

Rewrite this medical report in very simple plain language. Use short sentences. No medical jargon. Explain every medical term in everyday words. A 12-year-old should understand it. ## Summary Your metastatic colorectal cancer has specific genetic features that significantly impact your treatment options. The KRAS G12D mutation means you won't respond to certain targeted therapies like cetuximab or panitumumab, but you have other actionable mutations including PIK3CA E545K that could open doors to clinical trials. Your microsatellite stable (MSS) status and low tumor mutational burden indicate immunotherapy alone likely won't be effective, but combination approaches may still be relevant. The liver metastases are your primary concern for systemic treatment, and your CEA drop from 42 to 18 suggests your body is responding well to initial treatment. ## Key Findings - **[HIGH]** KRAS G12D mutation eliminates EGFR inhibitor options (cetuximab, panitumumab) but you need to understand alternative targeted approaches - **[HIGH]** PIK3CA E545K mutation present - this is actionable and could qualify you for PI3K inhibitor trials or combinations - **[HIGH]** Microsatellite stable (MSS) with low TMB (6) means standard immunotherapy approaches need careful consideration - **[MODERATE]** Liver-limited metastatic disease pattern may make you eligible for more aggressive local treatments - **[MODERATE]** CEA response (42→18) indicates treatment sensitivity but continued monitoring is critical ## Gaps in Your Workup - **[HIGH]** Missing HER2 amplification/overexpression testing - this is now standard and affects treatment eligibility - **[HIGH]** No documentation of RAS extended panel (NRAS, KRAS exons 3/4) - complete results needed for optimal treatment selection - **[MODERATE]** Unclear if BRAF V600E specifically tested or just BRAF wildtype reported - **[MODERATE]** Missing information about your performance status and treatment goals discussion ## Opportunities - **[HIGH]** PIK3CA mutation makes you eligible for multiple clinical trials combining PI3K inhibitors with standard chemotherapy - **[HIGH]** Liver-limited disease could qualify you for hepatic-directed therapies or aggressive surgical approaches after systemic treatment - **[MODERATE]** Consider HER2-targeted therapy trials if amplification is found on additional testing - **[MODERATE]** Explore combination immunotherapy approaches despite MSS status - some trials show benefit in specific populations ## Questions to Ask Your Doctor "Your genetic testing reveals a complex but potentially treatable cancer profile that requires careful treatment planning." "The KRAS mutation changes your treatment landscape, but other findings create new opportunities." "Understanding your complete molecular profile is crucial for accessing the most effective therapies." - What specific PI3K inhibitor clinical trials am I eligible for given my PIK3CA E545K mutation, and how do these combinations compare to standard chemotherapy? Why this matters: PI3K inhibitors combined with chemotherapy may offer better outcomes than chemotherapy alone for your specific mutation profile. - Should I have complete HER2 testing done immediately, and if positive, what treatment options does this open up? Why this matters: HER2 amplification occurs in 3-5% of colorectal cancers and has specific FDA-approved targeted therapies that could be more effective than chemotherapy. - Given my liver-limited metastases, am I a candidate for hepatic arterial infusion, radiofrequency ablation, or surgical resection after systemic treatment? Why this matters: Liver-directed therapies combined with systemic treatment can significantly improve outcomes for patients with liver-limited disease. - What are my options for combination immunotherapy trials despite being MSS, particularly approaches combining checkpoint inhibitors with other agents? Why this matters: Some MSS patients respond to combination immunotherapy approaches, especially when combined with targeted agents or chemotherapy. ## Recommended Next Steps - Request immediate HER2 amplification/overexpression testing (IHC and FISH) if not already completed - Ask your oncologist for a complete list of PI3K inhibitor clinical trials you qualify for at your treatment center - Schedule consultation with hepatobiliary surgeon to discuss liver-directed treatment options - Research clinical trials combining immunotherapy with targeted agents for MSS colorectal cancer - Request genetic counseling consultation to discuss hereditary cancer risk given your young age at diagnosis - Establish baseline imaging schedule and CEA monitoring frequency with your team ## Support for Your Next Appointment - Bring complete list of all medications, supplements, and allergies - Prepare questions about clinical trial eligibility and enrollment timelines - Ask for written treatment plan with alternative options if first-line therapy fails - Discuss fertility preservation if this is a concern before starting treatment - Request contact information for clinical trial coordinator - Bring insurance information and ask about financial assistance programs for targeted therapies - Ask about palliative care consultation for symptom management and quality of life support ## Sources & References - NCCN Clinical Practice Guidelines in Oncology: Colon Cancer Version 1.2024 - NCCN Clinical Practice Guidelines in Oncology: Rectal Cancer Version 5.2023 - Kopetz S, et al. Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer. New England Journal of Medicine 2019 - Siena S, et al. Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01). The Lancet Oncology 2021 - Tabernero J, et al. Pertuzumab, trastuzumab, and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB). The Lancet Oncology 2018 - André T, et al. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. New England Journal of Medicine 2020 - Modest DP, et al. Treatment sequencing for metastatic colorectal cancer. European Journal of Cancer 2019

Your Cancer Report in Simple Words

I'm going to break down your medical report into everyday language. Think of your cancer like a puzzle—we've found some important pieces, and that helps us know what treatments might work best for you.


What Your Cancer Looks Like

You have cancer that has spread to your liver. The cancer started in your colon (the large intestine), and now there are tumors in your liver too. This is called "metastatic" cancer—that just means it traveled from where it started.

The good news: Your body is responding to treatment. A marker in your blood called CEA dropped from 42 down to 18. Think of CEA like a smoke detector—when the number goes down, it means the fire (cancer) is getting smaller.


The Genetic Mutations (The Cancer's "Instruction Errors")

Your cancer cells have mistakes in their DNA (the instruction manual that tells cells how to work). We found three important ones:

KRAS G12D Mutation [VERY IMPORTANT]

What it means in plain language:

  • Your cancer has a broken instruction that makes it grow in a certain way
  • This broken instruction means two common cancer drugs (cetuximab and panitumumab) won't work for you
  • These drugs are like keys that only fit certain locks—your cancer's lock is different, so the keys don't fit

Why this matters: It narrows down which drugs to try, but it doesn't mean you're out of options.


PIK3CA E545K Mutation [VERY IMPORTANT]

What it means in plain language:

  • This is a different broken instruction in your cancer cells
  • This one is actually good news because doctors have drugs that target this specific mistake
  • Think of it like finding a weakness in the cancer that we can attack

Why this matters: This mutation opens doors to clinical trials (research studies testing new treatments) that might work better for you.


Microsatellite Stable (MSS) Status [IMPORTANT]

What it means in plain language:

  • Your cancer cells have a stable repair system (they can fix mistakes in their DNA pretty well)
  • This is different from some other colorectal cancers that have broken repair systems
  • Broken repair systems sometimes respond better to immunotherapy (drugs that wake up your immune system)

Why this matters: Standard immunotherapy alone probably won't work well for you, but combination treatments (mixing immunotherapy with other drugs) might still help.


Low Tumor Mutational Burden (TMB = 6) [MODERATE IMPORTANCE]

What it means in plain language:

  • Your cancer doesn't have a huge number of mutations (mistakes) in it
  • Cancers with lots of mutations are sometimes easier for the immune system to recognize and attack
  • Your cancer has fewer mutations, so it's better at hiding from your immune system

Why this matters: This confirms that immunotherapy alone probably won't be your best option.


What We're Missing (Important Tests Not Done Yet)

HER2 Testing [VERY IMPORTANT - DO THIS SOON]

What it means in plain language:

  • HER2 is a protein that sits on the outside of cancer cells
  • Some colorectal cancers have extra copies of this protein (called "amplification")
  • If your cancer has this, there are specific drugs that target it

Why this matters: About 3-5 out of every 100 colorectal cancers have HER2 amplification. If you have it, there are FDA-approved drugs (like trastuzumab deruxtecan) that could work really well for you. Ask your doctor to test for this immediately.


Complete RAS Panel [IMPORTANT]

What it means in plain language:

  • We tested for KRAS, but there are other related genes (NRAS) that should also be checked
  • We also need to check all the different parts of the KRAS gene to make sure we have the complete picture

Why this matters: This gives your doctor the full map of what's happening in your cancer cells.


BRAF Testing [MODERATE IMPORTANCE]

What it means in plain language:

  • BRAF is another gene that can be broken in cancer cells
  • We need to know for sure whether your cancer has a BRAF mutation or not

Why this matters: If you have a BRAF mutation, there are specific drug combinations that work well.


Your Liver Metastases (Cancer Spread to the Liver)

What it means in plain language:

  • The cancer has spread to your liver, but it's only in the liver (not spread everywhere)
  • This is actually better than if it had spread to many different organs

Why this matters: Because the cancer is only in one place, you might be eligible for special treatments that target the liver specifically:

  • Hepatic arterial infusion = doctors put chemotherapy drugs directly into the blood vessels that feed the liver tumor
  • Radiofrequency ablation = doctors use heat to burn away the tumor
  • Surgery = doctors might be able to remove the tumors after shrinking them with chemotherapy first

These treatments can work really well when cancer is liver-limited.


What Your CEA Drop Means

Your CEA went from 42 down to 18.

In plain language: This is like a smoke detector reading. When it goes down, it means the fire is getting smaller. Your body is responding well to the treatment you're already on. This is good news—it means the drugs you're taking are working.


Your Treatment Options Going Forward

Option 1: PI3K Inhibitor Clinical Trials [STRONG OPTION]

Because you have the PIK3CA E545K mutation, you can join research studies testing PI3K inhibitor drugs. These are drugs that block the broken instruction in your cancer cells.

How it works:

  • You'd take a PI3K inhibitor drug combined with standard chemotherapy
  • This combination might work better than chemotherapy alone for your specific mutation

Questions to ask your doctor:

  • "What PI3K inhibitor trials am I eligible for?"
  • "How do these trials compare to standard chemotherapy?"
  • "What are the side effects?"

Option 2: HER2-Targeted Therapy [IF YOU HAVE HER2 AMPLIFICATION]

If testing shows you have HER2 amplification, there's an FDA-approved drug called trastuzumab deruxtecan that works really well for colorectal cancer.

Why this matters: This drug has shown remarkable results in colorectal cancer patients with HER2 amplification.


Option 3: Liver-Directed Therapies [STRONG OPTION]

Because your cancer is only in the liver, you might be a candidate for:

  • Hepatic arterial infusion (putting chemo directly into liver blood vessels)
  • Radiofrequency ablation (burning away tumors with heat)
  • Surgery to remove tumors (after shrinking them first with chemotherapy)

Questions to ask your doctor:

  • "Should I see a liver surgeon to discuss my options?"
  • "Could we combine liver-directed therapy with systemic treatment?"
  • "What would the timeline look like?"

Option 4: Combination Immunotherapy Trials [POSSIBLE OPTION]

Even though you're MSS (which usually means immunotherapy alone won't work), some research studies are testing immunotherapy combined with other drugs for MSS patients.

Why this matters: Some MSS patients do respond when immunotherapy is combined with targeted drugs or chemotherapy.


Questions to Ask Your Doctor at Your Next Appointment

Question 1: About HER2 Testing

"Can we do HER2 amplification testing right away? If I have it, what treatment options does that open up?"

Why this matters: HER2 amplification occurs in 3-5% of colorectal cancers and has specific FDA-approved drugs that could be more effective than chemotherapy.


Question 2: About PI3K Inhibitor Trials

"Given my PIK3CA E545K mutation, what PI3K inhibitor clinical trials am I eligible for? How do these combinations compare to standard chemotherapy?"

Why this matters: PI3K inhibitors combined with chemotherapy may offer better outcomes than chemotherapy alone for your specific mutation.


Question 3: About Liver-Directed Therapies

"Given that my cancer is only in the liver, am I a candidate for hepatic arterial infusion, radiofrequency ablation, or surgical resection after systemic treatment?"

**

This is general information.

Upload your records for guidance specific to YOUR diagnosis — personalized to your biomarkers, stage, and treatment history.

Get guidance specific to your case

This answer covers general information. For guidance based on YOUR records, biomarkers, and treatment history: